

# in vivo

- International Journal of Experimental and Clinical Pathophysiology and Drug Research
- Published bimonthly by the International Institute of Anticancer Research
- Available online with Stanford University HighWire Press

ISSN (print): 0258-851X; ISSN (online): 1791-7549

## General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.
- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.
- IN VIVO supports: (a) the aims and the research program of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

## Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389; e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR websites: [www.iiar-anticancer.org](http://www.iiar-anticancer.org) and [www.iv.iiarjournals.org](http://www.iv.iiarjournals.org)

## Selection of Recent Articles

Cryopreservation of Viable Human Lung Tissue for Versatile Post-thaw Analyses and Culture. J.E. BAATZ, D.A. NEWTON, E.C. RIEMER, C.E. DENLINGER, E.E. JONES, R.R. DRAKE, D.D. SPYROPOULOS (*Charleston, SC, USA*)

Establishment and Characterization of New Orthotopic and Metastatic Neuroblastoma Models. E. DAUDIGEOS-DUBUS, L. LE DRET, V. ROUFFIAC, O. BAWA, I. LEGUERNEY, P. OPOLON, G. VASSAL, B. GEOERGER (*Orsay; Villejuif, France*)

Comparative Study of Prescribing Patterns of Tigecycline for Trial-Patients versus Non-Trial-Patients. J.J. HORSCHT, J.B. ZIMMERMANN, M.A. WEIGAND, T. BRUCKNER, E.O. MARTIN, T. HOPPE-TICHY, S. SWOBODA (*Heidelberg; Gießen, Germany*)

Effects of the Bifunctional Sulfoxide MMS350, A Radiation Mitigator, on Hematopoiesis in Long-Term Bone Marrow Cultures and on Radioresistance of Marrow Stromal Cell Lines. A. SHINDE, M.W. EPPERLY, S. CAO, D. FRANICOLA, D. SHIELDS, H. WANG, P. WIPF, M.M. SPRACHMAN, J.S. GREENBERGER (*Pittsburgh, PA, USA*)

The Need for Surgery in Acute Abdominal Pain: A Randomized Study of Abdominal Computed Tomography. P. JUVONEN, T. LEHTIMÄKI, M. ESKELINEN, I. ILVES, R. VANNINEN, P. MIETTINEN, H. PAAJANEN (*Kuopio, Finland*)

Inhibitory Action of Levocetirizine on the Production of Eosinophil Chemoattractants RANTES and Eotaxin In Vitro and In Vivo. A. KANEI, K. ASANO, K.-I. KANAI, A. FURUTA, K. SASAKI, H. SUZAKI (*Tokyo; Yokohama, Japan*)

Poor Memory Performance in Aged Cynomolgus Monkeys with Hippocampal Atrophy, Depletion of Amyloid Beta 1-42 and Accumulation of Tau Proteins in Cerebrospinal Fluid. H.S. DARUSMAN, J. PANDELAKI, R. MULYADI, D. SAJUTHI, I.A. PUTRI, O.H. KALLIOKOSKI, J. CALL, K.S.P. ABELSON, S.J. SCHAPIRO, A. GJEDDE, J. HAU (*Copenhagen; Aarhus, Denmark; Jakarta; Bogor, Indonesia; Leipzig, Germany; Bastrop, TX; Baltimore, MD, USA; Montreal, QC, Canada*)

Effects of Interactions between Progesterone and Prostaglandin on Uterine Contractility in Perfused Swine Uterus Model. J. KÜNZEL, K. GEISLER, T. MALTARIS, A. MÜLLER, I. HOFFMANN, H. SCHNEIDER, M.W. BECKMANN, R. DITTRICH, P.G. OPPELT (*Erlangen, Germany*)

Esophageal Radioprotection in Thoracic Irradiated Mice with Transgenic Lung Tumors by Swallowed JP4-039/F15. M.W. EPPERLY, J.P. GOFF, D. FRANICOLA, H. WANG, P. WIPF, S. LI, J.S. GREENBERGER (*Pittsburgh, PA, USA*)

Malignant Ascites in Ovarian Cancer and the Role of Targeted Therapeutics. E. SMOLLE, V. TAUCHER, J. HAYBAECK (*Graz, Austria*)

Increased DNA Integrity in Colorectal Cancer. G. LESZINSKI, J. LEHNER, U. GEZER, S. HOLDENRIEDER (*Munich; Bonn, Germany; Istanbul, Turkey*)

Circulating Human Fractalkine is Decreased Post-operatively After Orthopedic and Coronary Bypass Surgery. T. EKERFELDT, J. HELMERSSON-KARLQVIST, T. GORDH, A. LARSSON (*Uppsala, Sweden*)

Circulating miR-18a; A Sensitive Cancer Screening Biomarker in Human Cancer. S. KOMATSU, D. ICHIKAWA, H. TAKESHITA, R. MORIMURA, S. HIRAJIMA, M. TSUJIURA, T. KAWAGUCHI, M. MIYAMAE, H. NAGATA, H. KONISHI, A. SHIOZAKI, E. OTSUJI (*Kyoto, Japan*)

Antioxidant Effects of Lipophilic Tea Polyphenols on Diethylnitrosamine/Phenobarbital-induced Hepatocarcinogenesis in Rats. F. ZHOU, T. SHEN, T. DUAN, Y.-Y. XU, S.C. KHOR, Y.-F. ZHENG, S. HSU, J. DE STEFANO, J. YANG, L.-H. XU, X.-Q. ZHU (*Hangzhou, Zhejiang; Shanghai, PR China; Augusta, GA, USA*)

Anti-inflammatory Effects of Polihexanide and Polyethylene glycol in an In-vitro Study in Chronic Rhinosinusitis. R. BIRK, J. GROSSBAIER, C. ADERHOLD, J. STERN-STRATER, K. HÖRMANN, A. SAUTER, J.U. SOMMER (*Heidelberg, Germany*)

Anti-UV Activity of Kampo Medicines and Constituent Plant Extracts: Re-evaluation with Skin Keratinocyte System. T. KATO, S. HINO, N. HORIE, T. SHIMOYAMA, T. KANEKO, K. KUSAMA, H. SAKAGAMI (*Saitama; Tokyo, Japan*)

**FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST**

## Instructions to Authors 2014

*General Policy.* ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

*NIH Open Access Policy.* The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

*Copyright.* Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

*Format.* Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

*Manuscripts.* Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

*Figures.* All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

*Tables.* Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.

*References.* Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

*Nomenclature and Abbreviations.* Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC –IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

*Clinical Trials.* Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

*Ethical Policies and Standards.* ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 ([www.icmje.org](http://www.icmje.org)). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

*Submission of Manuscripts.* Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):

1. To submit your article online please visit: IIAR-Submissions (<http://www.iiar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org). Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (\*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:

John G. Delinasios  
 International Institute of Anticancer Research (IIAR)  
 Editorial Office of ANTICANCER RESEARCH,  
 IN VIVO, CANCER GENOMICS and PROTEOMICS.  
 1st km Kapandritiou-Kalamou Road  
 P.O. Box 22, GR-19014 Kapandriti, Attiki  
 GREECE

Submitted articles will not be returned to Authors upon rejection.

*Galley Proofs.* Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2014 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

# CANCER GENOMICS & PROTEOMICS

www.cgp.iarjournals.org

Print ISSN (2004-2012): 1109-6535

Online ISSN: 1790-6245

VOL. 1 (2004) - VOL. 9 (2012) (print and online)  
From VOL. 10 (2013) online – only and open access



## International Online Open Access Journal

**General Policy.** CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission or 1-2 months from acceptance.

CGP is published bimonthly by the **International Institute of Anticancer Research** and is available online with **Stanford University HighWire Press**: For more information please visit our website [www.cgp.iarjournals.org](http://www.cgp.iarjournals.org).

### Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389. E-mail: [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org); IIAR websites: [www.iiar-anticancer.org](http://www.iiar-anticancer.org) and [www.iiarjournals.org](http://www.iiarjournals.org)

### A Selection of Recent Papers

Genome-wide Transcriptional Sequencing Identifies Novel Mutations in Metabolic Genes in Human Hepatocellular Carcinoma (HCC). D.M. MEERZAMAN, C. YAN, Q.-R. CHEN, M.N. EDMONSON, C.F. SCHAEFER, R.J. CLIFFORD, B.K. DUNN, L. DONG, R.P. FINNEY, C.M. CULTRARO, Y. HU, Z. YANG, C.V. NGUYEN, J.M. KELLEY, S. CAI, H. ZHANG, J. ZHANG, R. WILSON, L. MESSMER, Y.-H. CHUNG, J.A. KIM, N.H. PARK, M.-S. LYU, I.H. SONG, G. KOMATSOULIS, K.H. BUETOW (*Rockville; Bethesda, MD; Memphis, TN, USA; Seoul; Ulsan; Cheon-An, South Korea*)

Crucial and Novel Cancer Drivers in a Mouse Model of Triple-Negative Breast Cancer. J.P.S. JOHNSON, P. KUMAR, M. KOULNIS, M. PATEL, K. SIMIN (*Worcester, MA; Bethesda, MD; Scranton, PA; New York, NY, USA; Singapore, Singapore*)

Cilia Gene Expression Patterns in Cancer. M. SHPAK, M.M. GOLDBERG, M.C. COWPERTHWAITTE (*Austin TX, USA*)

MicroRNA-150 Is Up-regulated in Extranodal Marginal Zone Lymphoma of MALT Type. N. GEBAUER, J. KUBA, A. SENFT, A. SCHILLERT, V. BERNARD, C. THORNS (*Lübeck, Germany*)

Proteomic Analysis of Soft Tissue Tumor Implants Treated with a Novel Polybisphosphonate. A. ALAIYA, J. FOX, S. BOBIS, G. MATIC, Z. SHINWARI, E. BARHOUSH, M. MÁRQUEZ, S. NILSSON, A.R. HOLMBERG (*Riyadh, Saudi Arabia; Manchester, UK; Stockholm, Sweden*)

Fucoidan-dependent Increased Membrane Component in HepG2: Effect of Fucoidan Is Not Due to Gene Expression. K. HAYAKAWA, T. NAGAMINE (*Tokyo; Gunma, Japan*)

Review: Prospects of Bacterial and Plant Protein-based Immunotoxins for Treatment of Cancer. U.H. WEIDLE, G. TIEFENTHALER, C. SCHILLER, E.H. WEISS, G. GEORGES, U. BRINKMANN (*Penzberg; Munich, Germany*)

A Novel Transmembrane Glycoprotein Cancer Biomarker Present in the X Chromosome. A.P. DELGADO, S. HAMID, P. BRANDAO, R. NARAYANAN (*Boca Raton, FL, USA*)

Rho Kinase Proteins Regulate Global miRNA Expression in Endothelial Cells. J.M. STILES, V. KURISSETTY, D.C. MITCHELL, B.A. BRYAN (*El Paso, TX, USA*)

Gene Expression Profiling of Circulating Natural Killer Cells in Head and Neck Squamous Cell Carcinoma. A. BOTTCHEER, J. OSTWALD, D. KOCZAN, R. KNECHT, B. KRAMP, S. DOMMERICH (*Hamburg; Rostock; Berlin, Germany*)

Serum and Tissue Metabolomics of Head and Neck Cancer. K. YONEZAWA, S. NISHIUMI, J. KITAMOTOMATSUDA, T. FUJITA, K. MORIMOTO, D. YAMASHITA, M. SAITO, N. OTSUKI, Y. IRINO, M. SHINOHARA, M. YOSHIDA, K.-I. NIBU (*Kobe, Japan*)

Isolation of Stem Cells Using Spheroids from Fresh Surgical Specimen: An Analytic Mini-review. I. AVITAL, A. STOJADINOVIC, H. WANG, C. MANNION, W.C.S. CHO, J. WANG, Y.G. MAN (*Richmond, VA; Hackensack, NJ; Washington, DC, USA; Hangzhou, China; Hong Kong, Hong Kong*)

Mutational Analysis of Gastrointestinal Stromal Tumors (GISTs): Procedural Approach for Diagnostic Purposes. R. PALMIROTTA, M.L. DE MARCHIS, G. LUDOVICI, B. LEONE, R. COVELLO, S. CONTI, L. COSTARELLI, D. DELLA-MORTE, P. FERRONI, M. ROSELLI, F. GUADAGNI (*Rome, Italy; Miami, FL, USA*)

# Subscription Order Form 2014

- Please enter a Subscription to ANTICANCER RESEARCH Volume 34 (2014).  
Annual subscription rates (2013): Institutional, Euro 1,650.00 print or online; Personal, Euro 780.00 print or online;  
Prices include rapid delivery and insurance.  
2014 online subscriptions include free online access to vol. 24 (2004) - 33 (2013).
- Please send me the following previous volumes (1-33) at 50% discount on the above rates.
- Payment is enclosed.  Please invoice.  
Checks should be made payable to Delinasios G.J. & CO G.P. (Athens, Greece)
- Please send me information about the International Institute of Anticancer Research (IIAR).

Name and Address: .....  
 .....  
 Tel: .....  
 Fax: ..... e-mail: .....  
 Signature:..... Date:.....

Please send this order to ANTICANCER RESEARCH, Subscription Office, IIAR, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel & Fax: +30-22950-53389, e-mail: subscriptions@iiar-anticancer.org

## Special 2014 Offers to Authors of ANTICANCER RESEARCH

(These offers are open to all authors of articles published in Anticancer Research from 1981-2014 on a basis of priority and availability. Effective from January to December 2014).

- **Included in Pubmed, Current Contents and all abstracting and indexing services**
- **Online with Stanford University HighWire Press**
- **Open access articles**



Your link to the essential information on cancer research published in the last 33 years.

- 1981-2013
- 33 volumes
- over 108,100 pages
- over 16,000 original articles
- 769 reviews
- over 73,300 authors
- Conference abstracts
- Special issues
- Book reviews
- Author-Subject Indexes

Please complete and send this order form to:  
 ANTICANCER RESEARCH, International Institute of Anticancer Research,  
 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece.

### Special Subscription Order Form 2014

- I am one of the authors of the article published in Anticancer Research Vol....., pp. ...., year .....
- Please enter my personal subscription to Anticancer Research 2014 (Volume 34) at the special Author's rate of Euro 390.00 (print or online).
- Please send me previous Volume No(s) ..... at Euro 195.00 (print) per volume.
- Please enter my personal combined 2014 subscription to Anticancer Research (Volume 34) and IN VIVO (Volume 28) at Euro 560.00 (print or online).
- My payment is enclosed.
- Please send me an invoice.  
Prices include rapid delivery and insurance. Checks should be made payable to Delinasios G.J. & CO G.P. (Athens, Greece).

Name and address: .....  
 .....  
 Tel-Fax: .....  
 e-mail: .....  
 Date and signature: .....



Early Metabolic Response on 18F-Fluorodeoxyglucose–Positron-emission Tomography/Computed Tomography After Concurrent Chemoradiotherapy for Advanced Stage III Non-small Cell Lung Cancer Is Correlated with Local Tumor Control and Survival. J.-U. JEONG, W.-K. CHUNG, T.-K. NAM, J.-Y. SONG, M. S. YOON, Y.-C. KIM, K.-S. KIM, I.-J. OH, H.-J. BAN, S. Y. KWON, H.-S. BOM, S.-J. AHN ( <i>Gwangju, Republic of Korea</i> ) .....	2517
Developing a Decision-making Model Based on an Interdisciplinary Oncological Care Group for the Management of Colorectal Cancer. D. GENOVESI, L. MAZZILLI, M. TRIGNANI, M. DI TOMMASO, A. NUZZO, E. BIONDI, N. TINARI, M. T. MARTINO, P. INNOCENTI, P. DI SEBASTIANO, L. MAZZOLA, C. LANCI, M. NERI, F. LATERZA, M. MARINO, G. FERRINI, A. SPADACCINI, A. FILIPPONE, E. DI GIANDOMENICO, A. MARULLI, G. PALOMBO, A. SPARVIERI, A. MARCHETTI, G. PIZZICANNELLA, F. PETRINI, M. DI FELICE, F. OTTAVIANI, A. MONTEODORISIO, M. DI NICOLA, G.A. CEFARO ( <i>Chieti, Italy</i> ).....	2525
Periapical Cemento-osseous Dysplasia: Clinicopathological Features. M. ROGHI, C. SCAPPARONE, R. CRIPPA, A. SILVESTRINI-BIAVATI, F. ANGIERO ( <i>Milan; Genova, Italy</i> ) .....	2533
A Novel Minimally Invasive Technique of High-Dose Rate Image-Based Intracavitary Brachytherapy for Endometrial Cancer Using a Single Fine and Soft, Flexible Applicator. K. MASUI, K. YOSHIDA, T. TAKENAKA, T. KOTSUMA, E. TANAKA, K. TATSUMI, H. YAMAZAKI, K. YAMADA ( <i>Kyoto; Osaka, Japan</i> ) .....	2537
Osteosarcoma of the Patella Mimicking Giant Cell Tumor: Imaging Features with Histopathological Correlation. M. AOKI, J. NISHIO, H. IWASAKI, M. MASAKI, Y. KAWAKAMI, T. NISHINO, H. OHJIMI, K. TAMURA, K. NABESHIMA, M. NAITO ( <i>Fukuoka, Japan</i> ) .....	2541
Gastrointestinal Stromal Tumor of Colon: A Case Report and Review of Literature. A.K. NIAZI, K. KALEY, M.W. SAIF ( <i>Islamabad, Pakistan; New Haven, CT; Boston, MA, USA</i> ) .....	2547
Preoperative 18F-FDG PET-CT Maximum Standardized Uptake Value Predicts Recurrence of Biliary Tract Cancer. M.-S. PARK, S.-M. LEE ( <i>Seoul, Republic of Korea</i> ) .....	2551
Re-irradiation of Spinal Cord Compression Due to Metastasis in Elderly Patients. D. RADES, J.N. EVERS, A. BAJROVIC, T. VENINGA, S.E. SCHILD ( <i>Lübeck; Hamburg, Germany; Tilburg, Netherlands; Scottsdale, AZ, USA</i> ) .....	2555
A Success Story: How a Single Targeted-Therapy Molecule Impacted on Treatment and Outcome of Diffuse Large B-Cell Lymphoma. M. MIAN, F. AUGUSTIN, F. KOCHER, E. GUNSILIUS, W. WILLENBACHER, A. ZABERNIGG, G. ZANGERL, H. OEXLE, S. SCHREIECK, M. SCHNALLINGER, M. FIEGL ( <i>Innsbruck; Kufstein; Zams; Hall; Reutte; St. Johann in Tirol, Austria</i> ) .....	2559
Detection and Cultivation of Circulating Tumor Cells in Malignant Pleural Mesothelioma. V. BOBEK, G. KACPRZAK, A. RZECHONEK, K. KOLOSTOVA ( <i>Prague, Czech Republic; Wroclaw, Poland</i> ) .....	2565
Lack of Association between KRAS Mutations and 18F-FDG PET/CT in Caucasian Metastatic Colorectal Cancer Patients. D. KRIKELIS, E. SKOURA, V. KOTOULA, P. RONDOGIANNI, N. PIANOU, A. SAMARTZIS, I. XANTHAKIS, G. FOUNTZILAS, I.E. DATSERIS ( <i>Thessaloniki; Athens, Greece</i> ) .....	2571
Contemporary Review of Large Adrenal Tumors in a Tertiary Referral Center. D. MEGE, D. TAIEB, A. LOWERY, A. LOUNDOU, C. DE MICCO, F. CASTINETTI, I. MORANGE, J.-F. HENRY, F. SEBAG ( <i>Marseille, France</i> ) .....	2581
Status of Anaplastic Lymphoma Kinase (ALK) in Malignant Mesothelioma. S. VARESANO, C. LEO, S. BOCCARDO, S. SALVI, M. TRUINI, P. FERRO, F. FEDELI, P. A. CANESSA, P. DESSANTI, M.P. PISTILLO, S. RONCELLA ( <i>Genova; La Spezia, Italy</i> ) .....	2589
ABSTRACTS OF THE 24th ANNUAL MEETING OF THE ITALIAN SOCIETY OF URO-ONCOLOGY (SIUrO). 22-24 June, 2014, <i>Bologna, Italy</i> .....	2593
Errata .....	2687

The Efficacy of Liver Resection for Multinodular Hepatocellular Carcinoma. K. NOJIRI, K. TANAKA, K. TAKEDA, M. UEDA, R. MATSUYAMA, K. TANIGUCHI, T. KUMAMOTO, R. MORI, I. ENDO ( <i>Yokohama; Chiba, Japan</i> ) .....	2421
Clinicopathological and Prognostic Significance of FOXM1 Expression in Esophageal Squamous Cell Carcinoma. A. TAKATA, S. TAKIGUCHI, K. OKADA, T. TAKAHASHI, Y. KUROKAWA, M. YAMASAKI, H. MIYATA, K. NAKAJIMA, M. MORI, Y. DOKI ( <i>Osaka; Nishinomiya, Hyogo, Japan</i> ) ....	2427
The Value of Elective Parotidectomy in Advanced Squamous Cell Carcinoma of the Skin of the Head. S. HOCH, N. FRANKE, N. KATABI, J. A. WERNER, A. TEYMOORTASH ( <i>Marburg, Germany</i> ) .....	2433
Fabry Disease Simulating Crohn's Ileitis. C.A. RUBIO, E. VILLNOW, B. SUNDELIN, E. ERIKSSON, K. DOLAPCSIEV, J. BJÖRK, R. BEFRITS, M. TENGVAR, H. IVERSEN ( <i>Stockholm, Sweden</i> ) .....	2437
Laparoscopic Radical Prostatectomy: 10 Years of Experience at a Single Institution. F. MANFERRARI, E. BRUNOCILLA, A. BACCOS, A. BERTACCINI, M. GAROFALO, M. BORGHESI, R. SCHIAVINA, G. MARTORANA ( <i>Bologna; Rimini, Italy</i> ) .....	2443
Neuroendocrine Pancreatic Carcinoma After Initial Diagnosis of Acute Postpartal Coeliac Disease in a 37-Year Old Woman – Fatal Coincidence or Result of a Neglected Disease? F. GUNDLING, A. NERLICH, W. HEITLAND, W. SCHEPP ( <i>Munich, Germany</i> ) .....	2449
A New Score Predicting Survival Prognosis After Whole-Brain Radiotherapy Alone for Brain Metastases in Elderly Patients. J.N. EVERS, S.E. SCHILD, B. SEGEDIN, V. NAGY, M.T. KHOA, N.T. TRANG, D. RADES ( <i>Lübeck, Germany; Scottsdale, AZ, USA; Ljubljana, Slovenia; Cluj-Napoca, Romania; Hanoi, Vietnam</i> ) .....	2455
Prognostic Value of a Cell-cycle Progression Score in Men with Prostate Cancer Managed with Active Surveillance After MRI-guided Prostate Biopsy - A Pilot Study. C. ARSOV, F. JANKOWIAK, A. HIESTER, R. RABENALT, M. QUENTIN, L. SCHIMMÖLLER, D. BLONDIN, G. ANTOCH, P. ALBERS ( <i>Düsseldorf, Germany</i> ) .....	2459
Influence of Thyroid Transcription Factor-1 on Fluorodeoxyglucose Uptake and Prognosis of Non-small Cell Lung Cancer. H. OOI, C. -Y. CHEN, Y. -C. HSIAO, W. -S. HUANG, B. -T. HSIEH ( <i>Taichung; Changhua, Taiwan, ROC</i> ) .....	2467
Prevention of Osteonecrosis of the Jaw in Patients with Bone Metastases Treated with Bisphosphonates. F. DE IULIIS, L. TAGLIERI, L. AMOROSO, S. VENDITTOZZI, L. BLASI, G. SALERNO, R. LANZA, S. SCARPA ( <i>Rome, Italy</i> ) .....	2477
Impact of Combination Chemotherapy with Itraconazole on Survival of Patients with Refractory Ovarian Cancer. H. TSUBAMOTO, T. SONODA, M. YAMASAKI, K. INOUE ( <i>Nishinomiya; Kobe; Hyogo, Japan</i> ) .....	2481
Second Malignancies in Philadelphia-negative Myeloproliferative Neoplasms—Single-Center Experience. J. KISSOVA, P. OVESNA, M. PENKA, A. BULIKOVA, I. KISS ( <i>Brno, Czech Republic</i> ) .....	2489
Advantages of Laparoscopy Versus Laparotomy in Extremely Obese Women (BMI>35) with Early-stage Endometrial Cancer: A Multicenter Study. R. TINELLI, P. LITTA, Y. MEIR, D. SURICO, L. LEO, A. FUSCO, S. ANGIIONI, E. CICINELLI ( <i>Vicenza; Padova; Novara; Bari; Cagliari, Italy</i> ) .....	2497
Number of Extraspinal Organs with Metastases: A Prognostic Factor of Survival in Patients with Metastatic Spinal Cord Compression (MSCC) from Non-small Cell Lung Cancer (NSCLC). D. RADES, A. WEBER, J.H. KARSTENS, S.E. SCHILD, T. BARTSCHT ( <i>Lübeck; Hannover, Germany; Scottsdale, AZ, USA</i> ) ....	2503
Early Manifestation of Communicating Hydrocephalus After Fractionated Stereotactic Radiotherapy for Aggressive Giant Atypical Prolactinoma. K. OHTAKARA, N. OHE, T. IWAMA, H. HOSHI ( <i>Gifu, Japan</i> ) ....	2509

Outcomes of Patients with Metastatic Cervical Cancer in a Phase I Clinical Trials Program. M.-M. HOU, X. LIU, J. WHELER, A. NAING, D. HONG, D. BODURKA, K. SCHMELER, A. TSIMBERIDOU, F. JANKU, R. ZINNER, S. PIHA-PAUL, C.-Y. HU, K. LU, R. KURZROCK, S. FU ( <i>Houston, TX; La Jolla, CA, USA; Taoyuan, Taiwan, ROC</i> ) .....	2349
Novel Serum Nucleosomics Biomarkers for the Detection of Colorectal Cancer. S. HOLDENRIEDER, Y. DHARUMAN, J. STANDOP, N. TRIMPOP, M. HERZOG, K. HETTWER, K. SIMON, S. UHLIG, J. MICALLEF ( <i>Bonn; Dresden, Germany; Namur, Belgium</i> ).....	2357
Preoperative Assessment of Peritoneal Carcinomatosis in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy Following Cytoreductive Surgery. E.M. PASQUAL, S. BERTOZZI, S. BACCHETTI, A.P. LONDERO, S.M.M. BASSO, D.A. SANTEUFEMIA, G.L. RE, F. LUMACHI ( <i>Pordenone; Padova; Udine, Italy</i> ).....	2363
HLA-A*02 in Relation to Outcome in Human Papillomavirus Positive Tonsillar and Base of Tongue Cancer. N. TERTIPIS, L. VILLABONA, C. NORDFORS, A. NASMAN, T. RAMQVIST, A. VLASTOS, G. MASUCCI, T. DALIANIS ( <i>Stockholm, Sweden</i> ).....	2369
A Phase II Trial of Two Durations of Bevacizumab Added to Neoadjuvant Gemcitabine for Borderline and Locally Advanced Pancreatic Cancer. K. SAHORA, M. SCHINDL, I. KUEHRER, A. EISENHUT, G. WERBA, C. BROSTJAN, B. TELEK, A. BA'SSALAMAH, J. STIFT, S.F. SCHOPPMANN, M. GNANT ( <i>Vienna, Austria</i> ).....	2377
Evidence that Mifepristone, a Progesterone Receptor Antagonist, Can Cross the Blood Brain Barrier and Provide Palliative Benefits for Glioblastoma Multiforme Grade IV. J.H. CHECK, C. WILSON, R. COHEN, M. SARUMI ( <i>Marlton; Camden, NJ; Philadelphia, PA, USA</i> ) .....	2385
The Clinical Impact of the Lymph Node Ratio as a Prognostic Factor after Resection of Pancreatic Cancer. Y. YAMAMOTO, H. IKOMA, R. MORIMURA, H. KONISHI, Y. MURAYAMA, S. KOMATSU, A. SHIOZAKI, Y. KURIU, T. KUBOTA, M. NAKANISHI, D. ICHIKAWA, H. FUJIWARA, K. OKAMOTO, C. SAKAKURA, T. OCHIAI, E. OTSUJI ( <i>Kyoto, Japan</i> ) .....	2389
Sequential Tyrosine Kinase Inhibitors (TKIs) in Metastatic Renal Cell Carcinoma: Results from a Large Cohort of Patients. P. BIONDANI, E. VERZONI, V. TORRI, L. PORCU, P. GRASSI, I. TESTA, F. DE BRAUD, G. PROCOPIO ( <i>Milan, Italy</i> ) .....	2395
The Impact of Combined Thoracoscopic and Laparoscopic Surgery on Pulmonary Complications After Radical Esophagectomy in Patients with Resectable Esophageal Cancer. N. KUBO, M. OHIRA, Y. YAMASHITA, K. SAKURAI, T. TOYOKAWA, H. TANAKA, K. MUGURUMA, M. SHIBUTANI, S. YAMAZOE, K. KIMURA, H. NAGAHARA, R. AMANO, H. OHTANI, M. YASHIRO, K. MAEDA, K. HIRAKAWA ( <i>Osaka, Japan</i> ) .....	2399
Survival of Patients Undergoing Cytoreductive Surgery for Metastatic Renal Cell Carcinoma in the Targeted-Therapy Era. M.R. ABERN, E. SCOSYREV, M. TSIVIAN, E.M. MESSING, T.J. POLASCIK, A.Z. DUDEK ( <i>Rochester, NY; Durham, NC; Chicago, IL, USA</i> ).....	2405
Mifepristone Causing Complete Remission of Rapidly Advancing Leukemia with Measurement of Progesterone-induced Blocking Factor. J.H. CHECK, D. CHECK, R. COHEN, M. SARUMI ( <i>Marlton; Camden, NJ; Philadelphia, PA, USA</i> ) .....	2413
Successful Management of Metachronous Liver Metastasis After Pancreaticoduodectomy for Pancreatic Ductal Carcinoma Using Hepatectomy and Chemotherapy: A Case Report. T. IIDA, Y. NAKABAYASHI, N. OKUI, H. SHIBA, M. OTSUKA, K. YANAGA ( <i>Tokyo; Saitama, Japan</i> ) .....	2417



MALDI Imaging on Tissue Microarrays Identifies Molecular Features Associated with Renal Cell Cancer Phenotype. S. STEURER, A.S. SEDDIQI, J.M. SINGER, A.S. BAHAR, C. EICHELBERG, M. RINK, R. DAHLEM, H. HULAND, G. SAUTER, R. SIMON, S. MINNER, E. BURANDT, P.R. STAHL, T. SCHLOMM, M. WURLITZER, H. SCHLÜTER ( <i>Hamburg, Germany</i> ).....	2255
Association of Caveolin-1 Genotypes with Gastric Cancer in Taiwan. C.-H. LIN, C.-C. LIN, C.-W. TSAI, W.-S. CHANG, C.-W. YANG, D.-T. BAU ( <i>Taichung, Taiwan, ROC</i> ).....	2263
Targeting Aurora Kinase A Inhibits Hypoxia-mediated Neuroblastoma Cell Tumorigenesis. C.V. ROMAIN, P. PAUL, S. LEE, J. QIAO, D.H. CHUNG ( <i>Nashville, TN, USA</i> ).....	2269
Natural Immunomodulators and their Stimulation of Immune Reaction: True or False? V. VETVICKA, J. VETVICKOVA ( <i>Louisville, KY, USA</i> ).....	2275
Contribution of Plasma Proteins, Albumin and Alpha 1-Acid Glycoprotein, to Pharmacokinetics of a Multi-targeted Receptor Tyrosine Kinase Inhibitor, Sunitinib, in Analbuminemic Rats. Y. TOYAMA, J. UEYAMA, H. NOMURA, I. TSUKIYAMA, H. SAITO, T. HISADA, K. MATSUURA, T. HASEGAWA ( <i>Nagakute; Nagoya; Toyota, Aichi, Japan</i> ).....	2283
Immunohistochemical Expression of STAM2 in Gastrointestinal Stromal Tumors. T. DŽOMBETA, K. KAPURALIN, M. ULAMEC, D. TOMAS, S. GAJOVIĆ, B. KRUŠLIN ( <i>Zagreb, Croatia</i> ).....	2291
miR-592 and miR-552 Can Distinguish Between Primary Lung Adenocarcinoma and Colorectal Cancer Metastases in the Lung. J. KIM, N.J. LIM, S.-G. JANG, H.K. KIM, G.K. LEE ( <i>Gyeonggi, Republic of Korea</i> ).....	2297
Relation of INHBA Gene Expression to Outcomes in Gastric Cancer after Curative Surgery. T. OSHIMA, K. YOSHIHARA, T. AOYAMA, S. HASEGAWA, T. SATO, N. YAMAMOTO, N. AKITO, M. SHIOZAWA, T. YOSHIKAWA, K. NUMATA, Y. RINO, C. KUNISAKI, K. TANAKA, M. AKAIKE, T. IMADA, MUNETAKA MASUDA ( <i>Yokohama, Kanagawa, Japan</i> ).....	2303
Genetics of Lymphocytes Influences the Emergence of Second Cancer in Chronic Lymphocytic Leukemia. M. BERNUÉS, M.A. DURÁN, G. PUGET, J. IGLESIAS, P. GALÁN, F.J. VERCHER, J. BESALDUCH, J. ROSELL ( <i>Palma de Mallorca; Maó; Ibiza, Balearic Islands, Spain</i> ).....	2311
Expression of Pcd4 Tumor Suppressor in Human Melanoma Cells. P.N. VIKHREVA, I.V. KOROBKO ( <i>Moscow, Russia</i> ).....	2315
<i>Clinical Studies</i>	
Levonorgestrel-impregnated Intrauterine Device Reduces Occurrence of Hyperplastic Polyps: A Population-based Follow-up Cohort Study. M. ARNES, B. HVIINGEL, A. ØRBO ( <i>Tromsø, Norway</i> ).....	2319
Impact of Epoetin-beta on Anemia and Health-related Quality of Life in Cancer Patients: A Prospective Observational Study Using the Generic 15D Instrument. J. MÄENPÄÄ, U. PUISTOLA, H. RISKKA, H. SINTONEN, O. SAARNI, E. JUVONEN, P.-L. KELLOKUMPU-LEHTINEN ( <i>Tampere; Oulu; Helsinki; Kuopio; Turku, Finland</i> ).....	2325
High Levels of Wilms' Tumor 1 (WT1) Expression Were Associated with Aggressive Clinical Features in Ovarian Cancer. Z. LIU, K. YAMANOUCHI, T. OHTA, S. MATSUMURA, M. SEINO, V. SHRIDHAR, T. TAKAHASHI, K. TAKAHASHI, H. KURACHI ( <i>Yamagata, Japan; Rochester, MN, USA</i> ).....	2331
Modern GERD Treatment: Feasibility of Minimally Invasive Esophageal Sphincter Augmentation. K. SCHWAMEIS, M. SCHWAMEIS, B. ZÖRNER, J. LENGLINGER, R. ASARI, F.M. RIEGLER, S.F. SCHOPPMANN ( <i>Vienna, Austria</i> ).....	2341

Fluorescent Resonance Energy Transfer Imaging of VEGFR Dimerization. Z. AHMADOVA, V. YAGUBLU, T. FÖRG, Y. HAJIYEVA, R. JESENOFSKY, M. HAFNER, M. KEESE ( <i>Mannheim; Frankfurt, Germany</i> ) .....	2123
Reproducibility of Histogram and Texture Parameters Derived from Intravoxel Incoherent Motion Diffusion-weighted MRI of FN13762 Rat Breast Carcinomas. Y.S. SONG, C.M. PARK, S.M. LEE, S.J. PARK, H.R. CHO, S.H. CHOI, J.M. LEE, B. KIEFER, J.M. GOO ( <i>Seoul, Republic of Korea; Erlangen, Germany</i> ) .....	2135
Serum Detection of Thymidine Kinase 1 as a Means of Early Detection of Lung Cancer. M.M. ALEGRE, M.J. WEYANT, D.T. BENNETT, J.A. YU, M.K. RAMSDEN, A. ELNAGGAR, R.A. ROBISON, K.L. O'NEILL ( <i>Provo, UT; Aurora, CO, USA; Cairo, Egypt</i> ) .....	2145
Novel Vitamin D Analogs as Potential Therapeutics: Metabolism, Toxicity Profiling, and Antiproliferative Activity. J. CHEN, J. WANG, T.-K. KIM, E.W. TIEU, E.K.Y. TANG, Z. LIN, D. KOVACIC, D.D. MILLER, A. POSTLETHWAITE, R.C. TUCKEY, A.T. SLOMINSKI, W. LI ( <i>Memphis; Knoxville, TN, USA; Crawley, WA, Australia</i> ) .....	2153
Overexpression of NOTCH-regulated Ankyrin Repeat Protein Is Associated with Breast Cancer Cell Proliferation. T. IMAOKA, T. OKUTANI, K. DAINO, D. IIZUKA, M. NISHIMURA, Y. SHIMADA ( <i>Chiba; Hiroshima, Japan</i> ) .....	2165
Gene Expression Profiling of Epithelial–Mesenchymal Transition in Primary Breast Cancer Cell Culture. L. MINAFRA, V. BRAVATÀ, G.I. FORTE, F.P. CAMMARATA, M.C. GILARDI, C. MESSA ( <i>Cefalù; Milan; Monza, Italy</i> ) .....	2173
Down-regulation of WAVE2, WASP Family Verprolin-Homologous Protein 2, in Gastric Cancer Indicates Lymph Node Metastasis and Cell Migration. H. JIA, Y. JIA, H.P. WEEKS, F. RUGE, X. FENG, R. MA, J. JI, J. REN, W.G. JIANG ( <i>Hohhot; Beijing, PR China; Cardiff, UK</i> ) .....	2185
The Real Deal: Using Cytochalasin B in Sonodynamic Therapy to Preferentially Damage Leukemia Cells. M. TRENDOWSKI, G. YU, V. WONG, C. ACQUAFONDATA, T. CHRISTEN, T.P. FONDY ( <i>Syracuse, NY, USA</i> ) .....	2195
Establishment of a Novel Cell Line from Intraductal Papillary Neoplasm of the Bile Duct. S. MURAKAMI, T. AJIKI, Y. HORI, T. OKAZAKI, T. FUKUMOTO, Y. KU ( <i>Kobe, Japan</i> ) .....	2203
Differential Expression of Galectin-1 and Galectin-3 in Canine Non-malignant and Malignant Mammary Tissues and in Progression to Metastases in Mammary Tumors. J.T. DE OLIVEIRA, A.J. DE MATOS, R. BARROS, C. RIBEIRO, A. CHEN, V. HESPANHOL, G.R. RUTTEMAN, F. GÄRTNER ( <i>Porto; Lisbon Portugal; Utrecht, Netherlands</i> ) .....	2211
Formyl Peptide Receptor 1 Expression Is Associated with Tumor Progression and Survival in Gastric Cancer. T.-Y. CHENG, M.-S. WU, J.-T. LIN, M.-T. LIN, C.-T. SHUN, K.-T. HUA, M.-L. KUO ( <i>Taipei; New Taipei City, Taiwan, ROC</i> ) .....	2223
Ouabain Enhances Lung Cancer Cell Detachment. T. RUANGHIRUN, V. PONGRAKHANANON, P. CHANVORACHOTE ( <i>Bangkok, Thailand</i> ) .....	2231
Novel Insights into the Expression of CGB1 & 2 Genes by Epithelial Cancer Cell Lines Secreting Ectopic Free hCG $\beta$ . B.B. BURCZYNSKA, L. KOBROULY, S.A. BUTLER, M. NAASE, R.K. ILES ( <i>London; Crieff, Scotland, UK; Poznan, Poland; Doha, Qatar; Houston, TX, USA</i> ) .....	2239
Global MicroRNA Profiling of Pancreatic Neuroendocrine Neoplasias. C. THORNS, C. SCHURMANN, N. GEBAUER, H. WALLASCHOFSKI, C. KÜMPERS, V. BERNARD, A.C. FELLER, T. KECK, J.K. HABERMANN, N. BEGUM, H. LEHNERT, G. BRABANT ( <i>Lübeck; Greifswald, Germany</i> ) .....	2249